These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 12116820)

  • 21. Outcome in the real-world of coronary high-risk intervention with drug-eluting stents (ORCHID) -- a single-center study comparing Cypher sirolimus-eluting with Taxus paclitaxel-eluting stents.
    Kumar S; Suresh V; Prendergast BD; Brooks NH; Wicks P; Levy RD; Ray SG; Bennett DH; Lee HS
    Catheter Cardiovasc Interv; 2006 Nov; 68(5):663-8. PubMed ID: 17034063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New drug-eluting stents, optimizing technique, and the problem of drug-eluting stent restenosis.
    Vaina S; Ong AT; Serruys PW
    Minerva Cardioangiol; 2005 Oct; 53(5):341-60. PubMed ID: 16179880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sirolimus-eluting stents: the novel application of basic science to coronary artery disease.
    Ir Med J; 2002; 95(7):196. PubMed ID: 12227523
    [No Abstract]   [Full Text] [Related]  

  • 24. Meta-analysis of randomized trials of drug-eluting stents versus bare metal stents in patients with diabetes mellitus.
    Boyden TF; Nallamothu BK; Moscucci M; Chan PS; Grossman PM; Tsai TT; Chetcuti SJ; Bates ER; Gurm HS
    Am J Cardiol; 2007 May; 99(10):1399-402. PubMed ID: 17493468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
    Grube E; Buellesfeld L
    Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sirolimus versus bare metal stent implantation in patients with total coronary occlusions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease (SCANDSTENT) trial.
    Kelbaek H; Helqvist S; Thuesen L; Kløvgaard L; Jørgensen E; Saunamäki K; Krusell LR; Bøtker HE; Engstrøm T; Jensen GV;
    Am Heart J; 2006 Nov; 152(5):882-6. PubMed ID: 17070149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Choosing a drug-eluting stent: a comparison between CYPHER and TAXUS.
    Perin EC
    Rev Cardiovasc Med; 2005; 6 Suppl 1():S13-21. PubMed ID: 15665793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
    Mehilli J; Kastrati A; Byrne RA; Bruskina O; Iijima R; Schulz S; Pache J; Seyfarth M; Massberg S; Laugwitz KL; Dirschinger J; Schömig A;
    J Am Coll Cardiol; 2009 May; 53(19):1760-8. PubMed ID: 19422982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peeling-off labels mounting evidence for benefit of drug-eluting stents with off-label use.
    Büttner HJ; Neumann FJ
    J Am Coll Cardiol; 2007 Nov; 50(21):2037-8. PubMed ID: 18021869
    [No Abstract]   [Full Text] [Related]  

  • 30. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry).
    Fröbert O; Lagerqvist B; Carlsson J; Lindbäck J; Stenestrand U; James SK
    J Am Coll Cardiol; 2009 May; 53(18):1660-7. PubMed ID: 19406341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis.
    Holmes DR; Leon MB; Moses JW; Popma JJ; Cutlip D; Fitzgerald PJ; Brown C; Fischell T; Wong SC; Midei M; Snead D; Kuntz RE
    Circulation; 2004 Feb; 109(5):634-40. PubMed ID: 14769686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Left main coronary artery stenting: crossing the Rubicon.
    Alfonso F
    J Am Coll Cardiol; 2009 May; 53(19):1769-72. PubMed ID: 19422983
    [No Abstract]   [Full Text] [Related]  

  • 34. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies.
    Moreno R; Fernández C; Hernández R; Alfonso F; Angiolillo DJ; Sabaté M; Escaned J; Bañuelos C; Fernández-Ortiz A; Macaya C
    J Am Coll Cardiol; 2005 Mar; 45(6):954-9. PubMed ID: 15766835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A stent is not just a stent: Stent construction and design do matter in its clinical performance.
    Lau KW; Johan A; Sigwart U; Hung JS
    Singapore Med J; 2004 Jul; 45(7):305-11; quiz 312. PubMed ID: 15221045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug-eluting stents for in-stent restenosis and acute myocardial infarction: present data from nonrandomized studies.
    Schofer J; Bode C; Silber S
    Herz; 2004 Mar; 29(2):195-200. PubMed ID: 15057441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The arsenal. The latest in drugs, surgery, and devices.
    Comarow A
    US News World Rep; 2003 Dec; 135(19):56, 58, 61. PubMed ID: 14712606
    [No Abstract]   [Full Text] [Related]  

  • 39. Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries.
    Ge J; Qian J; Wang X; Wang Q; Yan W; Yan Y; Fan B; Ge L; Liu X
    Catheter Cardiovasc Interv; 2007 Feb; 69(2):198-202. PubMed ID: 17195205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vascular brachytherapy versus sirolimus eluting stents for the treatment of in-stent restenosis: a prospective registry.
    Goy JJ; Urban P; Seydoux C; Couke P; De Benedetti E; Stauffer JC
    Heart; 2004 Dec; 90(12):1491-2. PubMed ID: 15547043
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.